Article
Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density.
Anticancer research - 1 Sept 2017
Takenaka Tomoya, Katayama Miku, Sugiyama Ayaka, Hagiwara Masaya, Fujii Ikuo, Takatani-Nakase Tomoka, Kobayashi Susumu S, Nakase Ikuhiko
Abstract excerpt
BACKGROUND/AIM: Gefitinib is a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and has been approved for the treatment of non-small cell lung cancers (NSCLCs) with EGFR mutations. Here we demonstrated that gefitinib induced a significantly enhanced biological activity of succinate-tetrazolium reductase (STR) in mitochondria and mitochondrial membrane potential in HCC827 cells (EGFR mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.